🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Oladapo Yeku

Harvard University

ORCID: 0000-0002-6319-1647

Also affiliated with Massachusetts General Hospital, Reproductive Science Center, Global Cancer Institute

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 14 papers. Top paper: “A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma”.

A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma

Journal of Translational Medicine(2020)10.1186/s12967-020-02523-5
N/A
0.870DataRank · unranked
19 citations

Andrea Russo, Hang Lee, David R. Spriggs, Oladapo Yeku

Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition

Frontiers in Immunology(2021)10.3389/fimmu.2021.663379
N/A
0DataRank · unranked
37 citations

Thapi D. Rao, Ian Laster, A. P. Kononenko, Terence J. Purdon, Pei Wang +5 more

Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies

Scientific Reports(2021)10.1038/s41598-021-82686-3
N/A
0DataRank · unranked
34 citations

Evan Smith, Oladapo Yeku, Kay J. Park, Ian Laster, Kwangkook Lee +8 more

Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents

Molecular Cancer Therapeutics(2022)10.1158/1535-7163.mct-21-0572
N/A
0DataRank · unranked
0 citations

Mengyao Xu, Stephanie Eng, Guangli Yang, Robin Manson, Néstor Rosales +9 more

664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors

Annals of Oncology(2023)10.1016/j.annonc.2023.09.1850
N/A
0DataRank · unranked
1 citations

T. Khanh, James M. Cleary, Aparna R. Parikh, Oladapo Yeku, Colin D. Weekes +13 more

Data from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents

(2023)10.1158/1535-7163.c.6543348
N/A
0DataRank · unranked
0 citations

Mengyao Xu, Stephanie Eng, Guangli Yang, Robin Manson, Néstor Rosales +9 more

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3135
N/A
0DataRank · unranked
36 citations

T. Khanh, Jeong Eun Kim, James M. Cleary, Aparna R. Parikh, Oladapo Yeku +26 more

Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair

Nature Communications(2024)10.1038/s41467-024-45693-2
N/A
0DataRank · unranked
19 citations

Boya Gao, Luyuan Zhang, Xudong Wang, Xiaolan Zhu, Haibo Yang +19 more

Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma

British Journal of Cancer(2024)10.1038/s41416-024-02621-x
N/A
0DataRank · unranked
14 citations

Dominique T. Zarrella, Venkatesh Pooladanda, Maryam Azimi, Eugene Kim, Shaan Kumar +15 more

Structural basis for antibody recognition of the proximal MUC16 ectodomain

Journal of Ovarian Research(2024)10.1186/s13048-024-01373-9
N/A
0DataRank · unranked
7 citations

Kay Perry, Mengyao Xu, Irva Veillard, Raj Kumar, Thapi D. Rao +4 more

Author Correction: Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair

Nature Communications(2024)10.1038/s41467-024-48241-0
N/A
0DataRank · unranked
0 citations

Boya Gao, Luyuan Zhang, Xudong Wang, Xiaolan Zhu, Haibo Yang +19 more

ABL1-mediated tyrosine phosphorylation of SYCP2 contributes to transcription-coupled homologous recombination and platinum resistance in ovarian cancer

NAR Cancer(2025)10.1093/narcan/zcaf031
N/A
0DataRank · unranked
2 citations

Xudong Wang, Melissa Long, Fengqi Zhang, Yumin Wang, Raj Kumar +5 more

Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages

Nature Communications(2020)10.1038/s41467-020-20140-0
N/A
0DataRank · unranked
168 citations

Oladapo Yeku, Sarwish Rafiq, Terence J. Purdon, Xue Dong, Lijing Zhu +10 more

First-In-Human Trial of Encapsulated Cell-Based Protein Producers for Localized IL-2 in Patients with High-Grade Serous Ovarian Carcinoma

medRxiv(2025)10.1101/2025.11.07.25339137
N/A
0DataRank · unranked
0 citations

Samira Aghlara-Fotovat, Jake Schladenhauffen, Jonathon DeBonis, Juan Carlos Amador-Molina, Amanda Nash +24 more